1-(4-Chlorophenyl)-3-(4-chlorophenyl)sulfonylimidazolidine-2,4-dione | 177711-26-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 1-(4-Chlorophenyl)-3-(4-chlorophenyl)sulfonylimidazolidine-2,4-dione
• CAS: 177711-26-1
• 化学式: C₁₅H₁₀Cl₂N₂O₄S
• 分子量: 385.2
• InChiKey: AYFNCNKRUGTVNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  83.1
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• FORTIFIER
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP1627638A1

  公开（公告）日：2006-02-22

  An agent for enhancing therapeutic or prophylactic effect of administering an inhibitor of renin-angiotensin system, such as candesartan cilexetil, on renal diseases is disclosed. The agent comprises a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.

  本发明公开了一种药剂，用于增强肾素-血管紧张素系统抑制剂（如坎地沙坦西来替酯）对肾脏疾病的治疗或预防效果。该制剂包括作为有效成分的特定前列腺素 I 衍生物，如贝拉前列素钠。
• Fortifier
  申请人：Toray Industries, Inc.

  公开号：US10149909B2

  公开（公告）日：2018-12-11

  An agent enhances the therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.

  一种可增强肾素-血管紧张素系统抑制剂对肾脏疾病的治疗或预防效果的制剂，包括作为有效成分的特定前列腺素 I 衍生物，如贝拉前列素钠。
• IMIDAZOLIDINE DERIVATIVE AND USE THEREOF
  申请人：SUNTORY LIMITED

  公开号：EP0721944B1

  公开（公告）日：2001-01-17
• BERAPROST AND A RENIN-ANGIOTENSIN SYSTEM INHIBITOR FOR USE IN THE TREATMENT OF RENAL DISEASES
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP1627638B1

  公开（公告）日：2017-07-12
• Drugs comprising chymase inhibitors and ACE inhibitors as effective ingredients
  申请人：Urata Hidenori

  公开号：US20080318961A1

  公开（公告）日：2008-12-25

  It is an object of the present invention to provide drugs which are effective for treatment of hypertension, cardiac disease (cardiac hypertrophy, cardiac failure, myocardial infarction, etc.), cerebral apoplexy, nephritis and the like. The invention also provides circulatory disease treatment agents in forms that allow combined use of chymase inhibitors and ACE inhibitors, and circulatory disease treatment methods which produce simultaneous chymase inhibition and ACE inhibition.